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a b s t r a c t
Intravenous positive inotropic agents play an important role in treating acute decompen-
sation of patients with heart failure due to left ventricular systolic dysfunction. Levosi-
mendan is a new positive inotropic agent having ATP-dependent potassium-channel
opening, and calcium-sensitizing effects, which increases cardiac contractility and perfor-
mance along with vasodilatatory action without increasing myocardial oxygen demand. We
report a case of a 12-year-old girl with viral myocarditis, dilated cardiomyopathy, biven-
tricular failure with severe left ventricular dysfunction, refractory to standard management,
and who was successfully improved with levosimendan.
# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier
India, Pvt. Ltd. All rights reserved.
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Levosimendan is a new pyridazinone-dinitrile derivative with
positive inotropic effects belonging to the category of
‘‘inodilators’’, which increases cardiac contractility and
performance along with vasodilatatory action. It is a calci-
um-sensitizing drug, which causes vasodilatation by opening
ATP-sensitive potassium channels without increasing myo-
cardial oxygen demand.1,2
We present a case of viral myocarditis with dilated
cardiomyopathy, biventricular failure, severe left ventricular
dysfunction, and refractory to standard management, which
successfully improved with levosimendan.* Corresponding author.
E-mail address: drsupriyabhu@gmail.com (S. Kushwah).
http://dx.doi.org/10.1016/j.ihj.2015.09.013
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier2. Case report
A 12-year-old girl, previously healthy, presented with moder-
ate to severe grade fever since 10 days. Following this, the child
developed abdominal pain and breathlessness, NYHA GRADE-
1, since 7 days. Breathlessness increased progressively and on
admission it was associated with orthopnea. The child
received symptomatic treatment from a local doctor. The
child had chest pain since 2 days and was referred to our
hospital. There was no history of any previous cardiac
problem, breathlessness, seizures, trauma, bluish discolor-
ation, tubercular contact, or hospitalization. On admission,
vital signs were as follows: pulse: 140/min, regular rhythm, low, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
Figs. 1 and 2 – Nonspecific ST and T wave segments, suggestive of myocarditis.
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84 mmHg; respiratory rate: 44/min; SpO2: 96% at room air.
Child had mild pallor, bilateral pitting pedal edema and raised
JVP. Cardiovascular system examination revealed cardiome-
galy and S3 gallop without any murmurs. Child had bilateral
ﬁne basal crepitations in chest with mild hepatomegaly. On
admission, all routine blood and urine investigations were
normal. Serum creatine kinase MB, Se. lactate, and Se.
troponin were high and were 74 units/L, 4.5 mmol/L, and
2.3 ng/mL, respectively. ECG was suggestive of features of
myocarditis. ECHO was done that was suggestive of dilated
cardiomyopathy, and biventricular failure with severe left
ventricular dysfunction with ejection fraction of only 15%.
Child was started on oxygen inhalation, iv ﬂuids, dobuta-
mine, Lasix, digoxin for DCM, and antibiotics and was
monitored strictly. Carvedilol and enalapril were added on
2nd day as there were no signs of improvement. Cause of
cardiomyopathy could never be established. On 2nd day, child
developed supraventricular tachycardia and diltiazem was
started. In view of ischemia heparin, aspirin and clopidogrelwere started. As ejection fraction did not improve even after 3
days of dobutamine, levosimendan infusion was started and
dobutamine was tapered and stopped. Patient improved
gradually. On 6th day LVEF improved up to 35%. Heparin
was stopped after 5 days and rest of the drugs were continued
(Figs. 1–3).
3. Discussion
Main aim for reporting this case is that novel drug levosi-
mendan can be used in refractory cardiac failure with low
ventricular function.3 Improvement after levosimendan was
remarkable. Oxygen, catecholamines, inotropes, phosphodi-
esterase inhibitors, diuretics, and drugs for afterload reduction
are still the basis for cardiac failure.
Levosimendan is a novel drug that acts as a myoﬁlament
Ca2+ sensitizer by acting on troponin with inotropic effects,
increases myocardial performance without substantial
changes in oxygen consumption, causes myocardial oxygen
Fig. 3 – Features suggestive of supraventricular tachycardia.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 5 7 – s 6 0 S59demand, and is with neutral effects on heart rhythm. It is 98%
bound to plasma proteins and completely metabolized prior to
excretion. Approximately 5% of the dose is converted in the
intestines to a highly active metabolite with an elimination
half-life of 75–80 h (compared to 1 hour elimination half-life
for levosimendan itself). This metabolite reaches a peak
plasma concentration in about 2 days after the termination
of the infusion and exhibits hemodynamic effects similar to
those of levosimendan. Because of the long half-life of the
active metabolite, these effects last for up to 7–9 days.4 A
wide range of levosimendan doses has been reported in
critically ill patients with doses differing signiﬁcantly
between studies (bolus 0–24 mg/kg, continuous infusion
0.05–0.2 mg/kg/min).5
Levosimendan opens both mitochondrial and sarcolemmal
Potassium ATP channels and is anti-ischemic with vasodila-
tory actions. In contrast to catecholamines and phosphodies-
terase-3 inhibitor, the potential for arrhythmia is also reduced
as total intracellular calcium levels are not raised but
sensitizes myoﬁlaments to calcium. The stabilization effect
is calcium dependant and levosimendan exerts its effects
during systole; it does not effect the duration of diastole and so
ventricular relaxation is not impaired. Consequently, ade-
quate ventricular ﬁlling and optimal coronary perfusion stilloccurs. Levosimendan has also been used in pulmonary
vasoconstriction and right ventricular dysfunction and
reduces pulmonary vascular resistance.6 In few clinical trials
comparing levosimendan versus dobutamine and milrinone
infusions in heart failure, levosimendan led to greater
improvement in hemodynamics and it was associated with
a lower risk of death at 31 and 180 days.7
In adults, the role of levosimendan is deﬁnitely established.
Till now, there are only few studies regarding usage of
levosimendan in children in the perioperative period with
normal left ventricular function to maintain cardiac output.
In one study in children, levosimendan allowed for
substantial reduction in catecholamine infusions with end-
stage or acute heart failure and also produced an objective
improvement in myocardial performance in acute heart
failure.8
In another study, the administration of levosimendan in
seven infants with severe myocardial dysfunction was well
tolerated intraoperatively. The mean arterial lactate levels
declined. Central venous oxygen saturation increased signiﬁ-
cantly 24 and 48 h after the onset of levosimendan infusion.9 In
addition to its inotropic and vasodilator effects, levosimendan
has several other important effects, including anti-inﬂamma-
tory effects and anti-apoptotic effects.10
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The current best evidence suggests that levosimendan is
beneﬁcial in improving cardiac performance and reducing the
left ventricular afterload. In addition, it may be effective in
reducing the need for catecholamine infusions and the
duration of critical care. Furthermore, it is safe and well
tolerated. It is a promising rescue drug for a potential clinical
beneﬁt in low-cardiac output and postcardiac surgery patients.
No data are available to validate its role with regard to its cost
effectiveness in comparison with milrinone. These encourag-
ing results need to be evaluated by larger, well-designed
clinical trials and its indications further elucidated. However,
the present evidence may not be enough to recommend it to
change the current practice in pediatrics.
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